Exclusive: Sanofi confirms the suspension of Alixiyou monoclonal antibody injection, cardiovascular product strategy in China will be upgraded

Today, it was learned from Sanofi that the news circulating in the market about Sanofi stopping the supply of Plavix in the Chinese market is true. Sanofi stated that the supply stoppage is due to global supply issues and the company's upgraded cardiovascular product strategy in China. At the end of last year, the company reached a cooperation agreement with Jiuxing Pharmaceutical for Aficamten in the Greater China region. It also recently announced the acquisition of the Greater China rights to Viazem Zen's investigational drug, Plesiranol sodium injection. The company's cardiovascular product strategy in China will undergo an overall upgrade. Sanofi also emphasized that they will continue to provide products in different fields to meet the needs of Chinese patients.